How does Cosentyx (secukinumab) work in the immune system?
Cosentyx is a monoclonal antibody that targets interleukin-17A (IL-17A). By binding IL-17A, it blocks the signal that drives inflammation in conditions where this pathway is active, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. This reduces inflammatory activity driven by IL-17A–dependent immune responses [1].
What changes happen to inflammation and immune signaling?
IL-17A is a key immune signaling molecule involved in inflammatory processes. When Cosentyx blocks IL-17A, it lowers the downstream inflammatory cascade that would otherwise recruit and activate immune cells in skin and joints. In practice, that means reduced skin inflammation (less redness, scaling, and thickness) and reduced joint/enthesitis inflammation in related diseases [1].
Does Cosentyx suppress the immune system like other biologics?
Cosentyx affects a specific part of immune signaling rather than broadly shutting down the whole immune system. Still, because it interferes with an immune pathway involved in host defense, it can increase susceptibility to certain infections. The risk is not “zero,” even though the mechanism is targeted to IL-17A rather than general immunosuppression [1].
What immune-related side effects do patients worry about most?
The most common safety concern tied to immune effects is infection risk. In clinical use, Cosentyx can be associated with infections (and in some cases, worsening or new infections), which is consistent with blocking an inflammatory immune pathway [1].
Can Cosentyx increase the risk of tuberculosis (TB) or other serious infections?
Cosentyx can raise the risk of infections because it alters immune responses. In practice, clinicians screen patients for certain infections (including TB) before starting biologic therapy, and they monitor for infection symptoms during treatment. This reflects standard precautions for drugs that modulate immune signaling [1].
What happens if someone gets an infection while on Cosentyx?
If a patient develops signs of infection, they should seek medical advice promptly. Clinicians may pause treatment depending on the type and severity of infection and the patient’s overall risk factors. The goal is to manage infection while avoiding unnecessary delays in care [1].
Who should be extra careful with Cosentyx’s immune effects?
Extra caution is typically needed in people with a history of recurrent infections, chronic or uncontrolled infections, or other significant risk factors for infection. Your prescriber may adjust the plan (monitoring frequency, timing, or treatment choice) based on your history and current health status [1].
Sources
- Cosentyx (secukinumab) prescribing information (U.S.). https://www.cosentyx.com/ (navigate to Prescribing Information)